Drug companies should not have the final say in the design of clinical trials.
Kurtzman
N A
NA
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001713:Biphenyl Compounds / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000592:standards*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D003928:Diabetic Nephropathies / Q000191:economics / Q000209:etiology / Q000517:prevention & control; D004345:Drug Industry; D004656:Enalapril / Q000627:therapeutic use; D006801:Humans; D000077405:Irbesartan; D019808:Losartan / Q000627:therapeutic use; D012107:Research Design / Q000592:standards*; D013777:Tetrazoles / Q000627:therapeutic use
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D013777:Tetrazoles; D004656:Enalapril; D000077405:Irbesartan; D019808:Losartan